Chemistry:CVT-301

From HandWiki
Revision as of 19:18, 30 December 2021 by imported>AnLinks (url)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

CVT-301 is an inhaled form of levodopa for the treatment of Parkinson's disease. It was developed by Civitas Therapeutics. A phase III clinical trial was completed in 2016.[1] A New Drug Application filed with the FDA in 2017[2] was rejected in a refuse-to-file letter.[3]

References

  1. ↑ "Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02240030. 
  2. ↑ "CVT-301 for Treatment of Parkinson's Disease OFF Episodes | Acorda.com" (in en). http://www.acorda.com/products/research-development/cvt-301. 
  3. ↑ "Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report" (in en-US). https://endpts.com/biogen-ucb-step-up-to-kick-the-tires-at-acorda-as-buyout-buzz-grows-report/. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CVT-301&oldid=891019"